Roche buys Piramed for up to $175mm, gets PI3-K inhibitors
In its first biopharmaceutical acquisition in exactly one year, Roche has agreed to buy private UK company Piramed (cancer, inflammation, and immune disorder therapeutics) for $160mm cash. Piramed shareholders are also eligible for $15mm in earn-outs should the biotech advance its lead cancer candidate into Phase II trials.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.